Implantation FailureNCT07486297
Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure
A study testing Acupuncture group in people with Implantation Failure, run by Huazhong University of Science and Technology at 1 site in China.
Trial summary
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Implantation Failure
- What is being tested?
- Acupuncture group
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 208 participants
- Where
- 1 siteChina
- Study dates
- 30 Jun 2026to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).
- Age: 20 to 40 years old.
- Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
- Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).
- Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.
Who cannot join
- Individuals planning to undergo preimplantation genetic diagnosis (PGD).
- Recipients of egg donations.
- Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
- Patients with known embryo-related factors leading to implantation failure.
- Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
- Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).
Show all 10Show fewer
- Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.
- Individuals with untreated hydrosalpinx;
- Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/m2.
- Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030
Pu Zhou, +8602783662379, tongjihlunli@163.com
About this study
Official title: A Multicenter Randomized Controlled Trial Evaluating the Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.
- Conditions
- Implantation Failure
- Being tested
- Placebo Group, Acupuncture group
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo GroupDevice
nonpenetrating placebo needles
Acupuncture groupDevice
indwelling intradermal needles
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | nonpenetrating placebo needles Receives: Device: Placebo Group |
| acupuncture group | Experimental | indwelling intradermal needles Receives: Device: Acupuncture group |
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical pregnancy
defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer
Measured: 1 year
Secondary outcomes (6)
β-hCG-positive pregnancy
defined as serum β-hCG concentration >10 mIU/mL on day 14 post-transfer
Measured: 1 year
Endometrial thickness
Endometrial thickness on Transformation Day
Measured: 1 year
endometrial blood flow
Measured: 1 year
anxiety assessment
Measured: 1 year
depression assessment
Measured: 1 year
sleep quality assessment
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start30 Jun 2026 (estimated)
- Primary completion28 Feb 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Implantation FailureStudies of the same condition, open and under way.
- More trials run by Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cui Hong Zheng, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07486297
- Sponsor's protocol ID
- TJ-IRB202510016
- Status last verified
- Jun 2026
- First submitted
- 25 Feb 2026
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Randomized Controlled Trial Evaluating the Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure
- ClinicalTrials.gov ID
- NCT07486297
- Acronym / sponsor ID
- TJ-IRB202510016
- Conditions
- Implantation Failure
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 208 participants (estimated)
- Lead sponsor
- Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 30 Jun 2026 (estimated)
- Primary completion
- 28 Feb 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Device: Placebo Groupnonpenetrating placebo needles |
| acupuncture group | Experimental | Device: Acupuncture groupindwelling intradermal needles |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).
- Age: 20 to 40 years old.
- Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
- Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).
- Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.
Key exclusion criteria (10 listed)
- Individuals planning to undergo preimplantation genetic diagnosis (PGD).
- Recipients of egg donations.
- Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
- Patients with known embryo-related factors leading to implantation failure.
- Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo Groupnonpenetrating placebo needles | Device | Placebo group |
| Acupuncture groupindwelling intradermal needles | Device | acupuncture group |
Primary outcome
clinical pregnancy
Time frame: 1 year
defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer
6 secondary outcomes
β-hCG-positive pregnancy
Time frame: 1 year
Endometrial thickness
Time frame: 1 year
endometrial blood flow
Time frame: 1 year
anxiety assessment
Time frame: 1 year
depression assessment
Time frame: 1 year
sleep quality assessment
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Implantation Failure
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
RecruitingObservational study
dPmax for Predicting Right Ventricular Failure After Left Ventricular Assist Device Implantation
Ventricular Dysfunction, Right
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
End Stage Renal Disease
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acupuncture group in people with Implantation Failure, run by Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical pregnancy (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.